S. 2696: Foundation for Enabling Biotechnology Innovation Act

This bill, known as the Foundation for Enabling Biotechnology Innovation Act, aims to create a nonprofit foundation under the National Science Foundation to enhance and promote biotechnology commercialization in the United States. Here’s a breakdown of its key components:

Establishment of the Foundation

The bill mandates the establishment of a nonprofit entity called the Foundation for Enabling Biotechnology Innovation. This foundation will be governed by a board of directors and will focus on augmenting biotechnology innovation efforts in collaboration with public and private sectors.

Mission and Objectives

The primary mission of the Foundation will be to accelerate the commercialization of biotechnology products, which includes:

• Supporting federal agencies involved in biotechnology.
• Fostering collaboration between various sectors—including industry, academia, and non-profits—to tackle challenges in commercialization.

Proposed Activities

The Foundation will undertake several activities, including:

• Promoting partnerships between public and private sectors to foster innovation.
• Bringing stakeholders together to provide expert recommendations on commercialization processes.
• Facilitating communication and collaboration among federal agencies and relevant stakeholders.
• Engaging the public through educational initiatives about biotechnology and associated regulatory matters.
• Helping U.S. biotechnology products gain market access both domestically and internationally.
• Funding studies and research to improve regulatory processes and market acceptance.
• Developing educational programs related to biotechnology commercialization.

Funding and Financial Structure

The Foundation will have the authority to receive various forms of funding, such as donations and grants, but will be prohibited from accepting funds from certain foreign entities of concern. The bill allows for the Foundation to be exempt from federal taxes and allows for the establishment of separate fund accounts specifically for its activities.

Governance

The governance structure will include a board with both voting and non-voting members. Voting members are required to have substantial experience in fields relevant to biotechnology, while federal employees cannot serve in voting capacities. The board will be responsible for setting priorities and overseeing the Foundation's mission.

Operational Oversight

The Foundation will employ a Chief Executive Officer appointed by the board, who will manage day-to-day operations and report on activities and financial status annually. There will also be provisions for annual audits to ensure transparency and accountability in operations.

Independence from Federal Regulation

Importantly, the Foundation will be independent and will not have regulatory authority over biotechnology products or activities, focusing instead on facilitation and support.

Authorization of Appropriations

To support its establishment and operations, the bill authorizes an appropriation of $4 million to be transferred annually from the National Science Foundation to the Foundation for its activities.

Integrity and Conflict of Interest Standards

To maintain integrity within its operations, the Foundation will develop standards to manage conflicts of interest and ensure that participants, including board members, are U.S. citizens or legal residents, thus safeguarding against foreign influence.

Intellectual Property

The Foundation will also establish guidelines for the ownership and licensing of intellectual property created through its activities.

Relevant Companies

• AMGN (Amgen Inc.): As a major biotechnology company, Amgen may benefit from increased support for commercialization processes.
• BIIB (Biogen Inc.): Biogen could see impacts in terms of collaboration opportunities and market access for their products.
• REGN (Regeneron Pharmaceuticals): Regeneron may engage with the Foundation for support in the commercialization of its biotechnology innovations.